About the Company
We do not have any company description for ANAVEX LIFE SCIENCES CORP. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences Corp. Announces Financial Results ... - Nasdaq
Anavex Life Sciences Corp., a biopharmaceutical company focused on treatments for neurological disorders, will release its financial results for the first fiscal quarter on February 12, 2025.
Anavex Life Sciences Corp. to Announce Fiscal Year 2024 ... - Nasdaq
Anavex Life Sciences Corp. announced that it will release its financial results for the fiscal year ended September 30, 2024, on December 23, 2024, and will host a conference call at 8:30 am ET ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript August 12, 2025 Anavex Life Sciences Corp. misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.13. Clint Tomlinson: Good morning, and ...
Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmac ...
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial ...
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease ...
Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ...
Anavex Life Sciences Corp (AVXL) reports a robust financial runway and unveils encouraging results for blarcamesine, despite ...
19,558 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by ...
Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44. The business’s 50 day moving average is $9.48 and its 200-day moving average is $7.99.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call ...
Anavex Life Sciences Corp. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning.
Anavex Life Sciences: A Promotional Company With Too Many Red Flags
Enter Anavex Life Sciences (NASDAQ: AVXL), a tiny company with less than 10 employees (until recently had only 1 employee) based in New York City, trading under the symbol AVXL, and the subject of ...
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call ...
Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.16. Clint Tomlinson: Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal ...
Similar Companies
Loading the latest forecasts...